Tyra Biosciences (TYRA) Common Equity (2020 - 2026)

Tyra Biosciences (TYRA) has 7 years of Common Equity data on file, last reported at $387.6 million in Q1 2026.

• Quarterly Common Equity rose 19.79% year-over-year to $387.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $387.6 million (up 19.79% YoY) and the FY2025 annual result came in at $259.2 million, down 24.47% from the prior year.
• Common Equity advanced to $387.6 million in Q1 2026, from $259.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $389.9 million in Q1 2024 to a low of $204.3 million in Q4 2023.
• A 5-year average of $296.1 million and a median of $280.5 million in 2025 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity surged 1761.82% — and 2025, when it retreated 24.47%.
• Tracing TYRA's Common Equity over 5 years: stood at $257.8 million in 2022, then declined by 20.78% to $204.3 million in 2023, then soared by 68.0% to $343.2 million in 2024, then slipped by 24.47% to $259.2 million in 2025, then jumped by 49.54% to $387.6 million in 2026.
• The last three Common Equity figures came in at $387.6 million (Q1 2026), $259.2 million (Q4 2025), and $280.5 million (Q3 2025), per Business Quant data.